The pharmaceuticals division currently generates $2 billion in annual sales — two-thirds of that in the U.S. market. The product division of the company does $9.6 billion in annual sales. Some of the drug unit’s products include Exalgo, an extended release opioid, and Pennsaid, a topical anti-inflammatory. Covidien said that entire process could take up to 18 months.
Related Articles on Pain Management:
Dr. Danzhu Guo and Dr. Thomas Wilkins Recognized by the National Committee for Quality Assurance Back Pain Recognition Program
7 Recent Efforts to Combat the Opioid Abuse Problem
New York City Launches Task Force to Combat Prescription Drug Problem
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
